Inhibition of uterine contractility by progesterone and progesterone metabolites: mediation by progesterone and gamma amino butyric acidA receptor systems.
Progesterone and several progesterone metabolites are capable of inhibiting uterine contractility. Some progesterone metabolites have shown little or no affinity for the progesterone receptor but have been found to be potent modulators of the GABAA receptor system. This study examined whether the inhibition of uterine contraction by progesterone and its metabolites was progesterone receptor-mediated or gamma amino butyric acidA (GABAA) receptor-mediated. Uterine contractions were measured in annular rings of uterine tissue, 5 mm in length, from diestrous II rats, under a fixed tension of 1 gram. The steroids tested were 3 beta-hydroxy-5 beta-pregnan-20-one (6 micrograms/ml), 5 beta-pregnane-3,20-dione (10 micrograms/ml), 3 alpha-hydroxy-5 alpha-pregnan- 20-one (3 alpha,5 alpha-THP, 27.5 micrograms/ml), and progesterone (40 micrograms/ml). All compounds significantly inhibited spontaneous uterine contractions when compared to controls. No effect was seen by either 16 micrograms/ml of the progesterone antagonist, RU486, or 32 micrograms/ml of the GABAA antagonist, pictrotoxin, when administered alone. However, when uterine tissues were exposed to a combination of the steroid and the antagonist, the effect of 3 beta-hydroxy-5 beta-pregnan-20-one and 3 alpha,5 alpha-THP was blocked by picrotoxin but not by RU486, indicating that the action of these steroids was mediated through the GABAA system. The effect of 5 beta-pregnane-3,20-dione and progesterone was effectively blocked by RU486 but not by picrotoxin, suggesting that their actions were mediated through the progesterone receptor system. These results indicate that multiple mechanisms exist in the uterus for inhibiting uterine contractility by progesterone and its metabolites.
Putnam
C D
CD
Department of Physiology and Endocrinology, Medical College of Georgia, Augusta 30912-3000.
Brann
D W
DW
Kolbeck
R C
RC
Mahesh
V B
VB
D043582:5-alpha-Dihydroprogesterone; D000818:Animals; D003864:Depression, Chemical; D004031:Diestrus; D004347:Drug Interactions; D005260:Female; D058787:GABA-A Receptor Antagonists; D015735:Mifepristone / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D011277:Pregnanediones / Q000494:pharmacology; D011280:Pregnanolone / Q000378:metabolism / Q000494:pharmacology; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology*; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*; D014590:Uterine Contraction / Q000187:drug effects* / Q000502:physiology
D043582:5-alpha-Dihydroprogesterone; D058787:GABA-A Receptor Antagonists; D015735:Mifepristone; D010852:Picrotoxin; D011277:Pregnanediones; D011280:Pregnanolone; D011374:Progesterone; D011963:Receptors, GABA-A; D011980:Receptors, Progesterone